Topline data were announced from a phase 3 trial evaluating bemarituzumab plus chemotherapy in individuals with gastric or gastroesophageal junction cancer with FGFR2b overexpression.

A total of 27.2 million people of all ages were uninsured in 2024, marking a nonsignificant increase from 25.0 million in 2023.

Participants could not effectively distinguish between medical responses written by a medical doctor and those written by an AI language model.

Perioperative durvalumab in combination with FLOT leads to significantly improved survival among individuals with resectable gastric and GEJ cancer.

Gallstone disease is linked to metabolic disorders, such as obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease.